AXIM Biotechnologies, Inc. (AXIM)
| Market Cap | 10.87M |
| Revenue (ttm) | 116,111 |
| Net Income (ttm) | -24.02M |
| Shares Out | 167.66M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 311,570 |
| Open | 0.0689 |
| Previous Close | 0.0690 |
| Day's Range | 0.0633 - 0.0689 |
| 52-Week Range | 0.0510 - 1.2200 |
| Beta | 2.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About AXIM
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid q...
News
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing L...
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface dise...
AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (...
AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarke...
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Diseas...
AXIM Biotechnologies CEO Issues Letter to Shareholders
AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system
AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (...
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (...
AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (D...
CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies
SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnosti...
AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests
Company's first rapid test to measure neutralizing antibodies is currently under FDA review Company's first rapid test to measure neutralizing antibodies is currently under FDA review
AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19
Company develops COVID-19 “Correlate of Protection” research to measure levels of neutralizing antibodies which protect from infection Company develops COVID-19 “Correlate of Protection” research to mea...
AXIM Biotechnologies' Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90%...
Publication in the Journal of Clinical Virology Highlights Effectiveness of the Rapid Test To Identifying Immunity Levels of Functional Antibodies, Preventing the Virus from Infecting Cells Publication ...
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 a...
AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical...
Dr. Nichols Strengthens Board with 25 Years of Optometry and Academic Experience Dr. Nichols Strengthens Board with 25 Years of Optometry and Academic Experience
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID...
AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisor...
Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board Dr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member Dr. Periman Joins Chairman Joseph Tauber as Advisory Board's Second Member
AXIM® Biotechnologies Appoints Joseph Tauber, MD, Chief Medical Officer and Chairman of its Medical Advisory Board
An Internationally Recognized Authority in Dry Eye Disease, Dr. Tauber has Participated in over 140 Research Studies as Principal Investigator An Internationally Recognized Authority in Dry Eye Disease,...
AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development
Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech Busby to Direct Dry Eye Disease Commercial Launch for Recently Acquired Diagnostic Tech
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA...
SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, CO...
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)'s for Diagnostic Testing of Dry Eye Disease
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and ca...
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological ...
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutr...
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and ...
AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and...
AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use...
SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological an...
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibod...
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological an...